Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2014 Dec;55(12):2699-705. doi: 10.3109/10428194.2014.891026. Epub 2014 Mar 18.

Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.

Author information

1
Department of Hematology, Provincial Hospital Affiliated to Shandong University , Jinan, Shandong , P. R. China.

Abstract

The antigen-dependent B-cell receptor (BCR) is triggered by binding to external antigens and transmits signals in normal B lymphocytes. Tonic signaling through the BCR plays a crucial role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). Spleen tyrosine kinase (Syk) is a key component of both BCR signals, and regulates multiple physiological functions of B lymphocytes. Studies have defined enhanced gene expression and protein expression of Syk in CLL cells which are closely related to the status of the immunoglobulin heavy chain variable region genes (IgVH). Recently, abrogating the BCR-induced signaling pathway by Syk inhibitors has represented a novel and active therapeutic approach for CLL. Studies of the correlation between Syk and ZAP-70 expression in CLL cells have brought a new perspective to determining the value of Syk in evaluating the effect of therapy and the prognosis of CLL. Therefore, we here review the role of Syk in the pathogenesis of CLL and provide an update of progress in the clinical development of Syk inhibitors.

KEYWORDS:

Syk; Syk inhibitors; ZAP-70; chronic lymphocytic leukemia

PMID:
24547708
DOI:
10.3109/10428194.2014.891026
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center